Ameriprise
RAPP

Ameriprise’s Rapport Therapeutics RAPP Stock Holding History

Ameriprise’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
14,696
+111
+0.8% +$4.08K ﹤0.01% 3607
2026
Q1 		$456K Sell
14,585
-209
-1% -$5.88K ﹤0.01% 3624
2025
Q4 		$449K Sell
14,794
-110,009
-88% -$3.04M ﹤0.01% 3666
2025
Q3 		$3.71M Buy
+124,803
New +$2.23M ﹤0.01% 2641

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Ameriprise's RAPP Position: Q2 2026 in Review

Ameriprise increased its Rapport Therapeutics (RAPP) stake by 0.76% in Q2 2026, buying an estimated $4.08K and bringing the position to 14,696 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #3607.

Ameriprise first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.71M in Q3 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Ameriprise held 14,696 shares of Rapport Therapeutics worth $612K as of Q2 2026.
  • Ameriprise bought 111 Rapport Therapeutics shares in Q2 2026, an estimated $4.08K.
  • Rapport Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3607 holding.
  • Ameriprise first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Ameriprise's Rapport Therapeutics position peaked at $3.71M in Q3 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.